TGFB1 and neoplasm: Bintrafusp alfa, designed as a checkpoint inhibitor and to “trap TGF-β” in the TME, has been shown to promote T- and NK-cell killing of tumor cells, promote antibody-dependent cell cytotoxicity, revert TGF-β-induced epithelial-mesenchymal phenotypic changes in cancer cells (tumor cell plasticity), and delay tumor growth in numerous mouse models of cancer [15,25,26,27].